PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 - New Market Report
GlobalData has released its new PharmaPoint Drug Evaluation report, "PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with...
View full press release